Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

Suvi Heinimäki; Vili Lampinen; Kirsi Tamminen; Minna M. Hankaniemi; Maria Malm; Vesa P. Hytönen; Vesna Blazevic

doi:10.1016/j.virol.2021.12.001

Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

Suvi Heinimäki, Vili Lampinen, Kirsi Tamminen, Minna M. Hankaniemi, Maria Malm, Vesa P. Hytönen, Vesna Blazevic

Department of Clinical Chemistry

Research output: Contribution to journal › Article › Scientific › peer-review

14 Citations (Scopus)

33 Downloads (Pure)

Abstract

Virus-like particles (VLPs) modified through different molecular technologies are employed as delivery vehicles or platforms for heterologous antigen display. We have recently created a norovirus (NoV) VLP platform, where two influenza antigens, the extracellular domain of matrix protein M2 (M2e) or the stem domain of the major envelope glycoprotein hemagglutinin (HA2) are displayed on the surface of the NoV VLPs by SpyTag/SpyCatcher conjugation. To demonstrate the feasibility of the platform to deliver foreign antigens, this study examined potential interference of the conjugation with induction of antibodies against conjugated M2e peptide, HA2, and NoV VLP carrier. High antibody response was induced by HA2 but not M2e decorated VLPs. Furthermore, HA2-elicited antibodies did not neutralize the homologous influenza virus in vitro. Conjugated NoV VLPs retained intact receptor binding capacity and self-immunogenicity. The results demonstrate that NoV VLPs could be simultaneously used as a platform to deliver foreign antigens and a NoV vaccine.

Original language	English
Pages (from-to)	89-97
Number of pages	9
Journal	VIROLOGY
Volume	566
Early online date	3 Dec 2021
DOIs	https://doi.org/10.1016/j.virol.2021.12.001
Publication status	Published - Jan 2022
Publication type	A1 Journal article-refereed

Keywords

HA2
Influenza virus
M2e
Norovirus
Platform
SpyTag/SpyCatcher
Vaccine
Virus-like particle
VLP

Publication forum classification

Publication forum level 1

ASJC Scopus subject areas

Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virol.2021.12.001Licence: CC BY

1-s2.0-S0042682221002415-mainFinal published version, 3.39 MBLicence: CC BY

https://urn.fi/URN:NBN:fi:tuni-202112219468Licence: CC BY

Cite this

@article{c896aa7346d04e53a9734e8b7247e0d1,

title = "Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology",

abstract = "Virus-like particles (VLPs) modified through different molecular technologies are employed as delivery vehicles or platforms for heterologous antigen display. We have recently created a norovirus (NoV) VLP platform, where two influenza antigens, the extracellular domain of matrix protein M2 (M2e) or the stem domain of the major envelope glycoprotein hemagglutinin (HA2) are displayed on the surface of the NoV VLPs by SpyTag/SpyCatcher conjugation. To demonstrate the feasibility of the platform to deliver foreign antigens, this study examined potential interference of the conjugation with induction of antibodies against conjugated M2e peptide, HA2, and NoV VLP carrier. High antibody response was induced by HA2 but not M2e decorated VLPs. Furthermore, HA2-elicited antibodies did not neutralize the homologous influenza virus in vitro. Conjugated NoV VLPs retained intact receptor binding capacity and self-immunogenicity. The results demonstrate that NoV VLPs could be simultaneously used as a platform to deliver foreign antigens and a NoV vaccine.",

keywords = "HA2, Influenza virus, M2e, Norovirus, Platform, SpyTag/SpyCatcher, Vaccine, Virus-like particle, VLP",

author = "Suvi Heinim{\"a}ki and Vili Lampinen and Kirsi Tamminen and Hankaniemi, {Minna M.} and Maria Malm and Hyt{\"o}nen, {Vesa P.} and Vesna Blazevic",

note = "Funding Information: This work was financially supported by Research on Viral diseases, V.A. Kotilainen, and Onni and Hilja Tuovinen, Tampere University Graduate School, and Academy of Finland [Projects 309455 and 335870]. The work was also funded by the Competitive State Research Financing of the Expert Responsibility Area of Fimlab Laboratories, and the Cancer Society of Finland.Technical assistance given by Eeva Jokela, Sanna Kav?n and Nina Koivisto from Vaccine development and immunology group/Vaccine Research Center of Tampere University is gratefully acknowledged. We also express our gratitude to members of the animal facility at Tampere University. We acknowledge infrastructure support by Biocenter Finland. Funding Information: This work was financially supported by Research on Viral diseases, V.A. Kotilainen, and Onni and Hilja Tuovinen, Tampere University Graduate School, and Academy of Finland [Projects 309455 and 335870]. The work was also funded by the Competitive State Research Financing of the Expert Responsibility Area of Fimlab Laboratories, and the Cancer Society of Finland . ",

year = "2022",

month = jan,

doi = "10.1016/j.virol.2021.12.001",

language = "English",

volume = "566",

pages = "89--97",

journal = "VIROLOGY",

issn = "0042-6822",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

AU - Heinimäki, Suvi

AU - Lampinen, Vili

AU - Tamminen, Kirsi

AU - Hankaniemi, Minna M.

AU - Malm, Maria

AU - Hytönen, Vesa P.

AU - Blazevic, Vesna

N1 - Funding Information: This work was financially supported by Research on Viral diseases, V.A. Kotilainen, and Onni and Hilja Tuovinen, Tampere University Graduate School, and Academy of Finland [Projects 309455 and 335870]. The work was also funded by the Competitive State Research Financing of the Expert Responsibility Area of Fimlab Laboratories, and the Cancer Society of Finland.Technical assistance given by Eeva Jokela, Sanna Kav?n and Nina Koivisto from Vaccine development and immunology group/Vaccine Research Center of Tampere University is gratefully acknowledged. We also express our gratitude to members of the animal facility at Tampere University. We acknowledge infrastructure support by Biocenter Finland. Funding Information: This work was financially supported by Research on Viral diseases, V.A. Kotilainen, and Onni and Hilja Tuovinen, Tampere University Graduate School, and Academy of Finland [Projects 309455 and 335870]. The work was also funded by the Competitive State Research Financing of the Expert Responsibility Area of Fimlab Laboratories, and the Cancer Society of Finland .

PY - 2022/1

Y1 - 2022/1

N2 - Virus-like particles (VLPs) modified through different molecular technologies are employed as delivery vehicles or platforms for heterologous antigen display. We have recently created a norovirus (NoV) VLP platform, where two influenza antigens, the extracellular domain of matrix protein M2 (M2e) or the stem domain of the major envelope glycoprotein hemagglutinin (HA2) are displayed on the surface of the NoV VLPs by SpyTag/SpyCatcher conjugation. To demonstrate the feasibility of the platform to deliver foreign antigens, this study examined potential interference of the conjugation with induction of antibodies against conjugated M2e peptide, HA2, and NoV VLP carrier. High antibody response was induced by HA2 but not M2e decorated VLPs. Furthermore, HA2-elicited antibodies did not neutralize the homologous influenza virus in vitro. Conjugated NoV VLPs retained intact receptor binding capacity and self-immunogenicity. The results demonstrate that NoV VLPs could be simultaneously used as a platform to deliver foreign antigens and a NoV vaccine.

AB - Virus-like particles (VLPs) modified through different molecular technologies are employed as delivery vehicles or platforms for heterologous antigen display. We have recently created a norovirus (NoV) VLP platform, where two influenza antigens, the extracellular domain of matrix protein M2 (M2e) or the stem domain of the major envelope glycoprotein hemagglutinin (HA2) are displayed on the surface of the NoV VLPs by SpyTag/SpyCatcher conjugation. To demonstrate the feasibility of the platform to deliver foreign antigens, this study examined potential interference of the conjugation with induction of antibodies against conjugated M2e peptide, HA2, and NoV VLP carrier. High antibody response was induced by HA2 but not M2e decorated VLPs. Furthermore, HA2-elicited antibodies did not neutralize the homologous influenza virus in vitro. Conjugated NoV VLPs retained intact receptor binding capacity and self-immunogenicity. The results demonstrate that NoV VLPs could be simultaneously used as a platform to deliver foreign antigens and a NoV vaccine.

KW - HA2

KW - Influenza virus

KW - M2e

KW - Norovirus

KW - Platform

KW - SpyTag/SpyCatcher

KW - Vaccine

KW - Virus-like particle

KW - VLP

U2 - 10.1016/j.virol.2021.12.001

DO - 10.1016/j.virol.2021.12.001

M3 - Article

AN - SCOPUS:85120789611

SN - 0042-6822

VL - 566

SP - 89

EP - 97

JO - VIROLOGY

JF - VIROLOGY

ER -

Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

Abstract

Keywords

Publication forum classification

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this